These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 22426469

  • 21. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
    Nameki D, Kodama E, Ikeuchi M, Mabuchi N, Otaka A, Tamamura H, Ohno M, Fujii N, Matsuoka M.
    J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.
    He Y, Liu S, Jing W, Lu H, Cai D, Chin DJ, Debnath AK, Kirchhoff F, Jiang S.
    J Biol Chem; 2007 Aug 31; 282(35):25631-9. PubMed ID: 17616522
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD.
    AIDS Rev; 2003 Aug 31; 5(4):214-21. PubMed ID: 15012000
    [Abstract] [Full Text] [Related]

  • 26. An optimized MM/PBSA virtual screening approach applied to an HIV-1 gp41 fusion peptide inhibitor.
    Venken T, Krnavek D, Münch J, Kirchhoff F, Henklein P, De Maeyer M, Voet A.
    Proteins; 2011 Nov 31; 79(11):3221-35. PubMed ID: 21989940
    [Abstract] [Full Text] [Related]

  • 27. [Inhibition of HIV-1 mediated cell-cell fusion by saponin fraction from Psidium guajava leaf].
    Mao QC, Zhou YC, Li RM, Hu YP, Liu SW, Li XJ.
    Zhong Yao Cai; 2010 Nov 31; 33(11):1751-4. PubMed ID: 21434438
    [Abstract] [Full Text] [Related]

  • 28. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.
    Teixeira C, Gomes JR, Gomes P, Maurel F, Barbault F.
    Eur J Med Chem; 2011 Apr 31; 46(4):979-92. PubMed ID: 21345545
    [Abstract] [Full Text] [Related]

  • 29. Identification of a D-amino acid decapeptide HIV-1 entry inhibitor.
    Boggiano C, Jiang S, Lu H, Zhao Q, Liu S, Binley J, Blondelle SE.
    Biochem Biophys Res Commun; 2006 Sep 08; 347(4):909-15. PubMed ID: 16854380
    [Abstract] [Full Text] [Related]

  • 30. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
    Mzoughi O, Gaston F, Granados GC, Lakhdar-Ghazal F, Giralt E, Bahraoui E.
    ChemMedChem; 2010 Nov 08; 5(11):1907-18. PubMed ID: 20922745
    [Abstract] [Full Text] [Related]

  • 31. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
    Welman M, Lemay G, Cohen EA.
    Virus Res; 2007 Mar 08; 124(1-2):103-12. PubMed ID: 17129629
    [Abstract] [Full Text] [Related]

  • 32. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.
    Yu F, Lu L, Du L, Zhu X, Debnath AK, Jiang S.
    Viruses; 2013 Jan 11; 5(1):127-49. PubMed ID: 23344560
    [Abstract] [Full Text] [Related]

  • 33. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
    Ding X, Zhang X, Chong H, Zhu Y, Wei H, Wu X, He J, Wang X, He Y.
    J Virol; 2017 Sep 15; 91(18):. PubMed ID: 28659478
    [Abstract] [Full Text] [Related]

  • 34. The potent human immunodeficiency virus type 1 (HIV-1) entry inhibitor HR212 blocks formation of the envelope glycoprotein gp41 six-helix bundle.
    Ouyang W, An T, Guo D, Wu S, Tien P.
    AIDS Res Hum Retroviruses; 2013 Mar 15; 29(3):613-20. PubMed ID: 23308369
    [Abstract] [Full Text] [Related]

  • 35. XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41.
    Zhao Q, Ernst JT, Hamilton AD, Debnath AK, Jiang S.
    AIDS Res Hum Retroviruses; 2002 Sep 20; 18(14):989-97. PubMed ID: 12396451
    [Abstract] [Full Text] [Related]

  • 36. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains.
    Lu L, Pan C, Li Y, Lu H, He W, Jiang S.
    Retrovirology; 2012 Dec 07; 9():104. PubMed ID: 23217195
    [Abstract] [Full Text] [Related]

  • 37. Targeting the sticky fingers of HIV-1.
    Blumenthal R, Dimitrov DS.
    Cell; 2007 Apr 20; 129(2):243-5. PubMed ID: 17448985
    [Abstract] [Full Text] [Related]

  • 38. HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor.
    Bashir T, Patgaonkar M, Kumar SC, Pasi A, Reddy KV.
    PLoS One; 2015 Apr 20; 10(4):e0124839. PubMed ID: 25915507
    [Abstract] [Full Text] [Related]

  • 39. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41.
    Liu S, Lu H, Zhao Q, He Y, Niu J, Debnath AK, Wu S, Jiang S.
    Biochim Biophys Acta; 2005 May 25; 1723(1-3):270-81. PubMed ID: 15823507
    [Abstract] [Full Text] [Related]

  • 40. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.
    Chong H, Qiu Z, Su Y, Yang L, He Y.
    AIDS; 2015 Jan 02; 29(1):13-21. PubMed ID: 25562490
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.